EDUCATION

Medical School

  • Johns Hopkins University School of Medicine , 1986 , Baltimore , MD

Residency

  • Stanford University , 1990 , Stanford , CA

Residency

  • Boston Children's Hospital , 1995 , Boston , MA

PROFESSIONAL HISTORY

Dr. Gonzalez serves as an expert for Psychology for Boston Children's Hospital Precision Medicine Service. For more information about the Precision Medicine Service please visit bostonchildrens.org/precisionmed.

CERTIFICATIONS

  • American Board of Psychiatry and Neurology, Psychiatry
  • American Board of Psychiatry and Neurology, Child and Adolescent Psychiatry
  • American Board of Psychiatry and Neurology, Forensic Psychiatry

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Early role for a Na+,K+-ATPase (ATP1A3) in brain development. Proc Natl Acad Sci U S A. 2021 Jun 22; 118(25). View abstract
  2. Underrepresentation of Phenotypic Variability of 16p13.11 Microduplication Syndrome Assessed With an Online Self-Phenotyping Tool (Phenotypr): Cohort Study. J Med Internet Res. 2021 03 16; 23(3):e21023. View abstract
  3. RCL1 copy number variants are associated with a range of neuropsychiatric phenotypes. Mol Psychiatry. 2021 05; 26(5):1706-1718. View abstract
  4. P300 amplitude attenuation in high risk and early onset psychosis youth. Schizophr Res. 2019 08; 210:228-238. View abstract
  5. Diagnostic Uncertainty in a Complex Young Man: Autism Versus Psychosis. J Dev Behav Pediatr. 2019 01; 40(1):72-74. View abstract
  6. De novo variant of TRRAP in a patient with very early onset psychosis in the context of non-verbal learning disability and obsessive-compulsive disorder: a case report. BMC Med Genet. 2018 11 13; 19(1):197. View abstract
  7. Young children with psychotic symptoms and risk for suicidal thoughts and behaviors: a research note. BMC Res Notes. 2018 Aug 10; 11(1):568. View abstract
  8. Social impairment and social language deficits in children and adolescents with and at risk for psychosis. Schizophr Res. 2019 02; 204:304-310. View abstract
  9. De novo ATP1A3 and compound heterozygous NLRP3 mutations in a child with autism spectrum disorder, episodic fatigue and somnolence, and muckle-wells syndrome. Mol Genet Metab Rep. 2018 Sep; 16:23-29. View abstract
  10. Potentially traumatic events in youth with and at clinical high risk for psychosis. Early Interv Psychiatry. 2019 08; 13(4):805-809. View abstract
  11. Suicidal behaviors and their relationship with psychotic-like symptoms in children and adolescents at clinical high risk for psychosis. Compr Psychiatry. 2017 10; 78:31-37. View abstract
  12. Review of Salient Investigational Drugs for the Treatment of Fragile X Syndrome. J Child Adolesc Psychopharmacol. 2017 Dec; 27(10):850-863. View abstract
  13. Social cognitive impairment in 22q11 deletion syndrome: A review. Psychiatry Res. 2017 07; 253:99-106. View abstract
  14. A Developmental Perspective on Social-Cognition Difficulties in Youth at Clinical High Risk for Psychosis. Harv Rev Psychiatry. 2017 Jan/Feb; 25(1):4-14. View abstract
  15. Suicidal behaviors in children and adolescents with psychotic disorders. Schizophr Res. 2017 01; 179:13-16. View abstract
  16. A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia. Cold Spring Harb Mol Case Stud. 2016 Sep; 2(5):a001008. View abstract
  17. Overlapping 16p13.11 deletion and gain of copies variations associated with childhood onset psychosis include genes with mechanistic implications for autism associated pathways: Two case reports. . 2016 May; 170A(5):1165-73. View abstract
  18. N100 Repetition Suppression Indexes Neuroplastic Defects in Clinical High Risk and Psychotic Youth. Neural Plast. 2016; 2016:4209831. View abstract
  19. Early auditory processing evoked potentials (N100) show a continuum of blunting from clinical high risk to psychosis in a pediatric sample. Schizophr Res. 2015 Dec; 169(1-3):340-345. View abstract
  20. Neurophysiological differences between patients clinically at high risk for schizophrenia and neurotypical controls--first steps in development of a biomarker. BMC Med. 2015 Nov 02; 13:276. View abstract
  21. Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1321-8. View abstract
  22. Epilepsy & behavior: My intellectual home for 15 years! Epilepsy Behav. 2014 Nov; 40:96. View abstract
  23. Comparing stimulant effects in youth with ADHD symptoms and epilepsy. Epilepsy Behav. 2014 Jul; 36:102-7. View abstract
  24. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry. 2014 Jul; 53(7):726-35. View abstract
  25. "RAGE-Control": A Game to Build Emotional Strength. Games Health J. 2013 Feb; 2(1):53-7. View abstract
  26. Management of psychotropic medication side effects in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2012 Oct; 21(4):713-38. View abstract
  27. Elevated rates of ADHD in mothers of children with comorbid ADHD and epilepsy. Neuropsychiatry (London). 2012 Oct 01; 2(5):385-391. View abstract
  28. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012 Sep 19; 4(152):152ra127. View abstract
  29. Longitudinal results of cognitive behavioral treatment for youths with inflammatory bowel disease and depressive symptoms. J Clin Psychol Med Settings. 2012 Sep; 19(3):329-37. View abstract
  30. Evidence-based treatment approach to autism spectrum disorders. Pediatr Ann. 2011 Nov; 40(11):569-74. View abstract
  31. Tolerability of atomoxetine for treatment of pediatric attention-deficit/hyperactivity disorder in the context of epilepsy. Epilepsy Behav. 2011 Jan; 20(1):95-102. View abstract
  32. The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders. Pharmaceuticals (Basel). 2010 Sep 10; 3(9):2986-3004. View abstract
  33. Transcranial magnetic stimulation provides means to assess cortical plasticity and excitability in humans with fragile x syndrome and autism spectrum disorder. Front Synaptic Neurosci. 2010; 2:26. View abstract
  34. Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy. Epilepsy Behav. 2010 Jul; 18(3):229-37. View abstract
  35. Use of a virtual community as a psychosocial support system in pediatric transplantation. Pediatr Transplant. 2010 Mar; 14(2):261-7. View abstract
  36. Association between attention-deficit/hyperactivity disorder and epilepsy in pediatric populations. Expert Rev Neurother. 2009 Dec; 9(12):1747-54. View abstract
  37. RAGE Control: Regulate and Gain Emotional Control. Stud Health Technol Inform. 2009; 149:335-43. View abstract
  38. Linkage analysis of attention deficit hyperactivity disorder. . 2008 Dec 05; 147B(8):1387-91. View abstract
  39. Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder. J Psychiatr Pract. 2008 May; 14(3):160-9. View abstract
  40. An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy. Expert Opin Investig Drugs. 2008 Jan; 17(1):77-84. View abstract
  41. Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav. 2008 Feb; 12(2):217-33. View abstract
  42. Oxcarbazepine is no more effective than placebo for reducing manic symptoms of bipolar I disorder in children and adolescents. Evid Based Ment Health. 2007 May; 10(2):59. View abstract
  43. Tolerability of selective serotonin reuptake inhibitors in thirty-nine children under age seven: a retrospective chart review. J Child Adolesc Psychopharmacol. 2007 Apr; 17(2):165-74. View abstract
  44. Psychiatric disorders and behavioral characteristics of pediatric patients with both epilepsy and attention-deficit hyperactivity disorder. Epilepsy Behav. 2007 May; 10(3):384-8. View abstract
  45. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord. 2008; 22(1):88-97. View abstract
  46. Pharmacological management of a youth with ADHD and a seizure disorder. J Am Acad Child Adolesc Psychiatry. 2006 Dec; 45(12):1527-32. View abstract
  47. A comparison of divalproex and oxcarbazepine in aggressive youth with bipolar disorder. J Psychiatr Pract. 2006 Jul; 12(4):214-22. View abstract
  48. Depression experience journal: a computer-based intervention for families facing childhood depression. J Am Acad Child Adolesc Psychiatry. 2006 Feb; 45(2):158-165. View abstract
  49. A Comparison of Divalproex and Risperidone in Pediatric Bipolar Disorder. Presented at the U.S. Psychiatric and Mental Health Congress. 2005. View abstract
  50. Tolerability of Olanzapine and Ziprasidone in Youths with Bipolar Disorder. Presented at the U.S. Psychiatric and Mental Health Congress. 2005. View abstract
  51. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit/Hyperactivity Disorder (ADHD). Presented at the American Academy of Child and Adolescent Psychiatry meeting. 2005. View abstract
  52. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit Hyperactivity Disorder (ADHD). Presented at the Child Neurology Society meeting. 2005. View abstract
  53. Tolerability of OROS-MPH 18 mg, 36 mg, and 54 mg in Pediatric Epilepsy Plus Attention-Deficit/Hyperactivity Disorder (ADHD). Presented at the International League Against Epilepsy meeting. 2005. View abstract
  54. A Comparison of Divalproex and Oxcarbazepine in Aggressive Youth with Bipolar Disorder. Presented at the Society for Biological Psychiatry meeting. 2005. View abstract
  55. Antiepileptic Drugs (AEDs) in the Treatment of Aggression in Children and Adolescents. Child and Adolescent Psychopharmacology News. 2005; 10(1):6-12. View abstract
  56. Psychopharmacology. . Behavioral and Developmental Pediatrics, A Handbook for Primary Care, Editors S Parker, B Zuckerman and M Augustyn. 2005; 83-89. View abstract
  57. Ziprasidone in Pediatric Patients: Efficacy and Tolerability. Presented at the World Psychiatric Association meeting. 2004. View abstract
  58. Comparisons of Response to Stimulant Preparations in Pediatric Epilepsy. Presented at the American Academy of Child and Adolescent Psychiatry meeting. 2004. View abstract
  59. Comparisons of Response to Stimulant Preparations in Pediatric Epilepsy. Presented at the American Neurological Association meeting. 2004. View abstract
  60. A Comparison of Divalproex, Gabapentin, and Oxacarbazepine in Aggressive Youth. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2004. View abstract
  61. Ziprasidone in Pediatric Patients: Efficacy and Tolerability. Presented at the New Clinical Drug Evaluation Unit (NCDEU). 2004. View abstract
  62. No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series. J Child Adolesc Psychopharmacol. 2004; 14(2):295-310. View abstract
  63. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination. J Am Acad Child Adolesc Psychiatry. 2003 Oct; 42(10):1227-33. View abstract
  64. No Seizure Exacerbation from Ziprasidone in Youth with Comorbid Epilepsy and Psychiatric Disorders: A Case Series. Presented at that 16th European College of Neuropsychopharmacology Congress. 2003. View abstract
  65. Comparison of Divalproex and Gabapentin: Effectiveness in Aggressive Youth. Presented at the 16th European College of Neuropsychopharmacology Congress. 2003. View abstract
  66. An Open Trial of the Safety and Efficacy of Mirtazepine in Children and Adolescents with Social Phobia. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2003. View abstract
  67. An Open Trial of the Safety and Efficacy of Mirtazapine in Children and Adolescents with Social Phobia. Presented at the Society for Biological Psychiatry meeting. 2003. View abstract
  68. Use of a computer-based application in a pediatric hemodialysis unit: a pilot study. J Am Acad Child Adolesc Psychiatry. 2003 Apr; 42(4):493-6. View abstract
  69. Depression Experience Journal: A computer-based intervention for families facing childhood depression. Available online: http://www.experiencejournal.com/depression. 2003. View abstract
  70. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex and their combination. Journal of the American Academy of Child & Adolescent Psychiatry. 2003; 42(10):1227-1233. View abstract
  71. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Institue for Psychiatric Services. 2002. View abstract
  72. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the International Conference on Child & Adolescent Mental Health. 2002. View abstract
  73. Aggressive Youth on Divalproex: Effectiveness as Reviewed in Medical Records. Presented at the Meeting of the American Psychiatric Association. 2002. View abstract
  74. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the Society for Biological Psychiatry. 2002. View abstract
  75. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Annual Boston Society of Neurology and Psychiatry Cobb Assembly. 2002. View abstract
  76. Stimulant Effectiveness in Well Controlled Versus Poorly Controlled Pediatric Epilepsy. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 2002. View abstract
  77. Future of technology to augment patient support in hospitals. Stud Health Technol Inform. 2002; 80:231-44. View abstract
  78. A case series of eight aggressive young children treated with risperidone. J Child Adolesc Psychopharmacol. 2002; 12(4):337-45. View abstract
  79. Aggressive Youth on Divalproex: Effectiveness as Reviewed in Medical Records. Journal of Adolescent Health. 2002; 30(2):125. View abstract
  80. Sertaline Treatment for Young Children: Systematic Review of Medical Records. Journal of Child and Adolescent Psychopharmacology. 2002; 12(4):294-5. View abstract
  81. Corticotropin releasing hormone increases apparent potency of adrenocorticotropic hormone stimulation of cortisol secretion. Med Hypotheses. 2001 Nov; 57(5):544-8. View abstract
  82. Risperidone Treatment in Pediatric Patients with Epilepsy: Systematic Review of Medical Records. Presented at the Meeting of the American College of Neuropsychopharmacology. 2001. View abstract
  83. An Open Study of Sustained Release Bupropion in Adults with ADHD and Substance Use Disorders. Presented at the Meeting of the American Academy of Child and Adolescent Psychiatry. 2001. View abstract
  84. 3 Years of a Pediatric Psychopharmacology Electronic Medical Records System. Presented at the Meeting of the American Academy of Child and Adolescent Psychiatry. 2001. View abstract
  85. Illness-related concerns of mothers of children with congenital heart disease. J Am Acad Child Adolesc Psychiatry. 2001 Jul; 40(7):847-54. View abstract
  86. Nefazodone for Depression in Bipolar and Non-Bipolar Youth: Systematic Review of Electronic Medical Records. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2001. View abstract
  87. Risperidone Treatment for Aggressive Preschool Children: Systematic Review of Medical Records. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2001. View abstract
  88. Method and system for displaying icons representing informational items stored in a database. 2001. View abstract
  89. Method and system for displaying icons representing informational items stored in a database. 2001. View abstract
  90. Zora: a pilot virtual community in the pediatric dialysis unit. Stud Health Technol Inform. 2001; 84(Pt 1):800-4. View abstract
  91. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001; 11(3):239-50. View abstract
  92. Cardiac Experience Journal: A computer-based intervention for families facing pediatric heart disease. Available online: http://www.experiencejournal.com. 2001. View abstract
  93. Zora: A Pilot Virtual Community in the Pediatric Dialysis Unit. MEDINFO 2001. Proceedings of the 12th World Congress on Medical Informatics. 2001; 10:800-804. View abstract
  94. Corticotropin releasing hormone increases Apparent Potency of ACTH Stimulation of Cortisol Secretion. Medical Hypothesis. 2001; 57(5):544-548. View abstract
  95. Implementation of an electronic medical record system in a pediatric psychopharmacology program. Int J Med Inform. 2000 Jul; 57(2-3):109-16. View abstract
  96. The experience journal: a computer-based intervention for families facing congenital heart disease. J Am Acad Child Adolesc Psychiatry. 2000 Jun; 39(6):727-34. View abstract
  97. Olanzapine in the Treatment of Bipolar Disorder in Juveniles. Presented at the New Clinical Drug Evaluation Unit (NCDEU) meeting. 2000. View abstract
  98. Bupropion SR for Attention Deficit Hyperactivity Disorder (ADHD)in Adults with Bipolar Disorder (BPD)and ADHD. Presented at the New Clincal Drug Evaluation Unit (NCDEU) meeting. 2000. View abstract
  99. Zora: A Pilot Virtual Community in the Pediatric Dialysis Unit. Presented at the Pediatric Academic Societies and American Academy of Pediatrics Joint Meeting. 2000. View abstract
  100. Epilepsy in children and adolescents. Child Adolesc Psychiatr Clin N Am. 1999 Oct; 8(4):671-94. View abstract
  101. Using 'off the shelf', computer programs to mine additional insights from published data: diurnal variation in potency of ACTH stimulation of cortisol secretion revealed. Comput Methods Programs Biomed. 1999 Mar; 58(3):227-38. View abstract
  102. Interactive Storytelling Environments: Coping with Cardiac Illness at Boston's Children's Hospital. Proceedings of CHI'98, Association of Computing CHI'98 Machinery Special Interest Group in Computer-Human Interaction Conference. 1998; 603-609. View abstract
  103. Experience journals: using computers to share personal stories about illness and medical intervention. Stud Health Technol Inform. 1998; 52 Pt 2:1325-9. View abstract
  104. Experience Journals: Using Computers to Share Stories About Illness and Medical Intervention. MEDINFO 98. Proceedings of the 9th World Congress on Medical Informatics. 1998; 1323-1327. View abstract
  105. Experience Journals: Using Computers to Share Stories About Illness and Medical Intervention. MEDINFO 98. Proceedings of the 9th World Congress on Medical Informatics. 1998; 1323-1327. View abstract
  106. Computer Modeling of Human Data Reveals CRH Increases the Potency of ACTH Effect on Cortisol and Rate of Cortisol Degradation With Differences in Sexually Abused Girls. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 1997. View abstract
  107. Computer Modeling of Human Data Reveals CRH Increases the Potency of ACTH Effect on Cortisol and Rate of Cortisol Degradation With Differences in Sexually Abused Girls. Presented at the Dynamical Neurosciences Symposium at the Society of Neurosciences Meeting. 1996. View abstract
  108. A Neural Network Approach to Modelling Personality Development. Presented at the Dynamical Neurosciences Symposium at the Society of Neurosciences Meeting. 1996. View abstract
  109. Book Review of Child and Adolescent Depression: Clinical and Research Perspectives. New England Journal of Medicine. 1996. View abstract
  110. Transexuals: MCMI-II Severe Personality Disorder Incidence Depends on Setting and Sex. Presented at the Harvard Consolidated Department of Psychiatry Research Day. 1995. View abstract
  111. A Computer Simulation of the Hypothalamic-Pituitary-Adrenal Axis. Presented at the American College of Neuropsychopharmacology Meeting. 1994. View abstract
  112. A Computer Stimulation of the Hypothalamic-Pituitary-Adrenal Axis. Proceedings of the Annual Symposium on Computer Applications in Medical Care. 1994; 1010. View abstract
  113. Book Review of The Kaspar Hauser Syndrome of "Psychosocial Dwarfism": Deficient Statural, Intellectual and Social Growth Induced by Child Abuse. New England Journal of Medicine. 1994; 331(15):1031. View abstract
  114. A computer simulation of the hypothalamic-pituitary-adrenal axis. Proc Annu Symp Comput Appl Med Care. 1994; 1010. View abstract
  115. Rates of Personality Disorders in Gender Dysphorics Using a Self Report Inventory, the MCMI-II. Presented at the XIII International Sympsium on Gender Dysphoria. 1993. View abstract
  116. Using neural networks to model personality development. Med Hypotheses. 1993 Aug; 41(2):123-30. View abstract
  117. Testing the psychogenic vomiting diagnosis. Four pediatric patients. Am J Dis Child. 1991 Aug; 145(8):913-6. View abstract
  118. Testing the Psychogenic Vomitting Diagnosis: Four Pediatric Patients. American Journal of Diseases of Children. 1991; 148(8):913-916. View abstract
  119. Postsynaptic localization of 5-HT1D receptor binding sites in human caudate. Exp Neurol. 1991 Jul; 113(1):28-30. View abstract
  120. Serotonin receptor and reuptake sites: pharmacologic significance. J Clin Psychiatry. 1990 Apr; 51 Suppl:5-12; discussion 13. View abstract
  121. Aphrodiesiology: History, Folklore and Efficacy. In: The Pharmacology and Endocrinology of Sexual Function. Handbook of Sexology; series editors, Money, J., and Musaph, H. 1988; 6:499-515. View abstract
  122. Reductions of Serotonergic Receptors in Alzheimer's Disease: An Autoradiographic Study. Abstract presented at the Meeting of the American Academy of Neurology, 1986. 1986. View abstract